Bristol-Myers Squibb Company announced positive Week 52 data from its Phase 3 POETYK PsA-1 trial, confirming the efficacy of Sotyktu for psoriatic arthritis. Additionally, new findings show sustained safety and efficacy for up to four years of Sotyktu treatment for lupus patients. Sotyktu is an oral TYK2 inhibitor approved for moderate-to-severe plaque psoriasis globally.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company known for discovering, developing, and selling innovative products worldwide. While BMY is a solid investment, consider AI stocks for greater upside potential and less downside risk. Explore our report on the best short-term AI stock for potential growth opportunities.

For those seeking investment opportunities beyond Bristol-Myers Squibb Company, look into AI stocks for potential growth. Consider exploring stocks that have the potential to double in three years or hidden AI stocks with growth potential. This article is originally published on Insider Monkey and offers insights into investment opportunities.

Read more at Yahoo Finance: Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data